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Movement Disorders Associated With
Hemochromatosis
Niraj Kumar, Philippe Rizek, Bekim Sadikovic, Paul C. Adams, Mandar Jog
ABSTRACT: Background: Hereditary hemochromatosis (HH) is a genetic disorder causing pathological iron deposition and functional
impairment of various organs, predominantly the liver. We assessed patients with HH for the presence of movement disorders. Methods:
We reviewed the charts of 616 patients with HH who attended hemochromatosis clinic at London Health Sciences Centre, London, ON,
Canada, from 1988 to 2015. Results: We found three HH patients with movement disorders, without any other major systemic
manifestation. One had parkinsonism, another had chorea, and the third had tremor. All three patients had evidence of iron deposition in the
brain, affecting the basal ganglia in the first two, and the dentate nucleus, red nucleus, and substantia nigra in the third patient. In addition to
the C282Y homozygous mutation in the HFE gene, two of our patients had non-HFE gene mutations. Conclusion: HH should be
considered in the differential diagnosis of movement disorders with pathological brain iron deposition. We report for the first time chorea in
a patient with HH. Non-HFE gene mutations may predispose HH patients to iron deposition in the brain.

RÉSUMÉ: Troubles du mouvement associés à l’hémochromatose. Contexte : L’hémochromatose héréditaire (HH) est une maladie génétique qui
entraîne des dépôts pathologiques de fer et des altérations fonctionnelles au niveau de différents organes, particulièrement au niveau du foie. Nous avons
examiné la présence de troubles du mouvement chez des patients atteints de HH. Méthodologie : Nous avons revu les dossiers de 616 patients atteints de
HH traités à la clinique d’hémochromatose du London Health Sciences Centre de London, Ontario, Canada, de 1988 à 2015. Résultats : Nous avons
identifié 3 patients atteints de HH qui présentaient des troubles du mouvement sans autre manifestation systémique importante. Un patient présentait du
parkinsonisme, un autre de la chorée et le troisième du tremblement. Ces trois patients avaient des dépôts de fer dans le cerveau, soit au niveau des noyaux
gris centraux chez les deux premiers et dans le noyau dentelé, le noyau rouge et le locus niger chez le troisième patient. En plus de la mutation homozygote
C282Y dans le gène HFE, deux de nos patients avaient des mutations génétiques qui n’étaient pas dans le gène HFE. Conclusion : L’HH devrait être
incluse dans le diagnostic différentiel des troubles du mouvement chez les patients qui présentent des dépôts pathologiques de fer dans le cerveau. Nous
rapportons pour la première fois de la chorée chez un patient atteint d’HH. Des mutations dans des gènes autres que HFE pourraient prédisposer les patients
atteints d’HH à la formation de dépôts de fer dans le cerveau.

Keywords: Hemochromatosis, HFE Gene, Chorea, Parkinsonism, Tremor
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Hereditary hemochromatosis (HH) is a genetic disorder of iron
metabolism in which progressive iron accumulation leads to
pathological iron deposition and functional impairment of various
organs that may become irreversible if not treated early.1 The
typical hemochromatosis patient is homozygous for the C282Y
mutation in the HFE gene on the short arm of chromosome 6.1,2
In HH, iron deposition predominantly occurs in the liver,
pancreas, heart, joints, gonads, and skin.1 HH usually does not
involve the nervous system, with even fewer reported cases
presenting with movement disorders.3-13 We describe three HH
patients affected by isolated movement disorders without any
other major systemic features of HH and review the literature with
an aim to explore a possible causal relationship between HH and
neurological manifestations.
MATERIALS AND METHODS
The hemochromatosis clinic at London Health Sciences Centre,
London, ON, Canada, was started in 1988, and a multidimensional
database has been created since that time on all C282Y
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homozygotes. All patients were assessed by the same physician
(PCA) who is a recognized expert in this field. Clinical data were
collected from this database reviewed by PCA, and physical
examination including neurological examination was performed.
The patients in the group that had isolated neurological symptoms
and possible signs involving the central nervous system (n = 3) were
separated from the entire group and referred to the movement disorder clinic. The next-generation sequencing (NGS) of these
patients was extracted from the data performed at the London Health
Sciences Clinical Molecular Genetics Laboratory using the hyperferritinemia gene panel. Testing involved NGS and copy number
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analysis for 15 iron-related genes (HFE2, STEAP3, SLC40A1,
SLC25A38, TF, CP, HFE, TFR2, FTH1, CDAN1, B2M, HAMP,
FTL, SEC23B, ALAS2) using the custom Roche Nimblegen capturebased library enrichment (Madison, WI) and Illumina NGS platform
(San Diego, CA). Sequencing included all coding exons for each
gene with additional 20 nucleotides of intronic sequence around
each exon. This assay is clinically validated to meet the sensitivity
and specificity of Sanger sequencing and multiplex ligation dependent probe amplification combined, with mean exon sequence depth
of 1000 × and minimum sequence depth of 100 × at a single
nucleotide resolution, along with custom copy number assessment
of the NGS sequence data. Variants were interpreted by a certified
clinical molecular geneticist (BS), and classified using the American
College of Medical Genetic guidelines (PMID: 25741868). Variants
classified as pathogenic, likely pathogenic, or variants of unknown
clinical significance were confirmed using Sanger sequencing or
multiplex ligation dependent probe amplification.
RESULTS
Clinical details were available on 616 patients (362 males and
254 females) who were C282Y homozygotes. All patients
underwent detailed hematological and biochemical workup for
HH along with the genetic testing. The three patients were referred
to the movement disorder clinic where they were assessed by at
least one of the neurologists (NK, PR, and MJ). Examination
included detailed neurological assessment including movement
disorder assessment (n = 3) as well as other investigations as
deemed necessary to rule out other possible etiologies, including
neuroimaging (brain magnetic resonance imaging [MRI] scan,
n = 3), electroencephalogram (n = 1), copper studies for Wilson’s
disease (n = 3), Huntington disease (HD) gene test (n = 1), liver
Fibroscan (n = 3), liver MRI scan (n = 1), and liver biopsy (n = 1).
Case details for each patient follow.
Case Reports
Patient 1
This 61-year-old man of Irish and Portuguese ancestry was
first diagnosed with HH at the age of 55 years. There was
incidental detection of liver iron on his MRI scan when he was
involved as a control subject in a research study. He had no
children. There was no family history of HH. His initial serum
ferritin level was 1183 µg/l with increased transferrin saturation
(87.5%). Genetic testing confirmed a C282Y homozygous
mutation in the HFE gene, and a heterozygous variant of unknown
clinical significance c.3188C > T (p.Thr1063Met) in the codanin
gene (congenital dyserythropoietic anemia-1, CDAN1) on NGS.
Phlebotomy normalized his serum ferritin. Two years after being
diagnosed with HH, he developed rest and action tremor and loss
of dexterity in his left upper limb. His cognition was preserved. He
had full extraocular movements with saccadic pursuits and slow
vertical saccades. He had facial hypomimia, mild hypophonia,
rigidity, and bradykinesia of the left upper and lower extremities,
as well as a slow shuffling gait with reduced left arm swing.
Laboratory workup showed normal complete blood count, thyroid
function test, creatinine, glucose, ceruloplasmin, and 24-hour
urinary copper. He had no evidence of liver involvement or
diabetes mellitus. His liver Fibroscan was normal. He continued
on regular phlebotomy every 3 months. His brain MRI scan
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showed symmetrical abnormal T1 hyperintensity in the lentiform
nuclei and substantia nigra bilaterally (Figure 1). He was started
on levodopa-carbidopa (100/25 mg) 1 tablet by mouth four times
per day. On his follow-up 6 months later, there was improvement
in his parkinsonism.
Patient 2
This 64-year-old man of Scottish heritage was diagnosed with
HH at the age of 60 when he was detected to have increased serum
ferritin (3403 µg/l) and transferrin saturation (95%) while being
investigated for vertigo. Genetic testing confirmed a C282Y
homozygous mutation in the HFE gene, and heterozygous
pathogenic mutation c.212G > A (p.Gly71Asp) in the hepcidin gene
(hepcidin antimicrobial peptide, HAMP) on NGS. His family history
is significant, with his brother having HH without neurological
manifestations. He was treated with phlebotomy, which normalized
his serum ferritin. An otolaryngologist ruled out peripheral causes of
vertigo. Echocardiography was normal, but he had a positive
tilt-table test. One year after being diagnosed with HH, he developed
intermittent left-sided, low-amplitude, choreiform movements
primarily involving the fingers, and, occasionally, the hand and left
foot. He had hypometric saccades, but no bradykinesia, rigidity,
tremor, ataxia, or weakness. Laboratory workup showed normal
serum electrolytes (sodium, potassium, and calcium), blood glucose,
thyroid function test, creatine kinase, liver enzymes, bilirubin,
creatinine, ceruloplasmin, and 24-hour urinary copper. He had
decreased serum vitamin B12 that was supplemented. Genetic
testing for HD was negative. Electroencephalogram was normal.
Brain MRI scan showed T2 hypointensity with low signal
on susceptibility-weighted imaging (SWI) in both caudate and
lentiform nuclei, consistent with iron deposition (Figure 2), and
to a lesser extent in bilateral dorsolateral nuclei of the thalami and
dentate nuclei of the cerebellum. Incidental small asymptomatic
bilateral cerebellar and left corona radiata infarcts were also seen.
There was no evidence of liver involvement or diabetes mellitus. His
liver Fibroscan was normal. His chorea improved on tetrabenazine
25 mg oral twice daily. He developed mild parkinsonism as a side
effect of tetrabenazine. His brain MRI scan was repeated after
phlebotomy treatment and was unchanged.
Patient 3
This 66-year-old female patient was first diagnosed with HH at
the age of 52 years. Her initial serum ferritin level was 1391 µg/l and
transferrin saturation was 94%. She had no family history of HH.
Genetic testing confirmed a C282Y homozygous mutation in the
HFE gene, without non-HFE mutations on NGS. She was initially
treated with phlebotomy, which was discontinued after her serum
ferritin normalized. At the age of 56, she developed tremor in her
head and bilateral upper extremities. There was no history of slowness, stiffness, gait, or balance abnormality. She had normal cognition and speech. On examination, she had postural and action tremor
in both upper extremities with no rest tremor. There was no
appendicular ataxia and her gait was normal. Her brain MRI scan
showed low signal on SWI in the dentate, red nuclei and substantia
nigra, consistent with iron deposition (Figure 3). Laboratory workup
showed normal complete blood count, glucose, liver and thyroid
function tests, creatinine, and serum ceruloplasmin. Her liver
Fibroscan was slightly abnormal at 11.8 (normal < 7). Liver biopsy
showed a moderate parenchymal iron overload (hepatic iron
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Figure 1: Brain MRI scan shows symmetrical T1 hyperintensity in the lentiform nuclei (A) and substantia
nigra (B).

concentration: 145.4 µmol/g dry weight; reference range: 0-35) with
no evidence of fibrosis, consistent with HH. She resumed treatment
at the age of 62 when her serum ferritin increased to 3513 µg/l and
transferrin saturation reached 95.5%, with a maintenance regimen of
phlebotomy every 4 months after normalization of her iron stores.
Her tremor improved on propranolol 40 mg oral twice daily.
DISCUSSION
Iron is essential for the development and functioning of the brain,
and required in myelin synthesis, neurotransmitter and enzyme
function, and energy production.14 The brain is second only to the
liver among the organs with maximal physiological storage of iron.9
In the brain, iron distribution is not homogenous, and the globus
pallidus contains the highest concentration, followed by the red
nucleus, substantia nigra, putamen, and the dentate nucleus.14,15
Several neurodegenerative disorders, including Parkinson disease
(PD), pantothenate kinase associated neurodegeneration, aceruloplasminemia, neuroferritinopathy, and Friedreich’s ataxia, are
associated with increased brain iron.7,14 Increased free iron, in
disorders such as HH, generates free radicals that lead to cellular
damage by overwhelming the detoxification system of the cell.10
The blood-brain barrier is thought to protect against brain iron
overload.14 The majority of HFE protein resides within the brain
capillaries, choroid plexus, and ependymal cells along with
transferrin receptors, and influence iron uptake by the brain.15,16
This view was supported by the postmortem finding in HH
patients with iron deposition in the choroid plexus without any
abnormal basal ganglia pigmentation,3,17 however, Williams et al
reported postmortem iron deposition in the basal ganglia, locus
coeruleus, and dentate nuclei in a case of HH with parkinsonism
related to multiple system atrophy, parkinsonian type.13 Iron
deposition in the basal ganglia and cerebellum may cause movement disorders in HH.11 The reason for the susceptibility of the
basal ganglia to iron deposition is not well-understood, but it may
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be related to selective neuronal uptake and abnormal vascular or
axonal transport along white matter tracts connecting these
nuclei.18 T2 hypointensity and T1 hyperintensity, as well as low
signal susceptibility artifact on SWI, help detect brain iron on
MRI scans.4,5,10,11,19 Neuroimaging in HH may show basal
ganglia calcification and slight sulcal prominence on brain computed tomography,3 T1 hyperintensity and T2 hypointensity in the
basal ganglia (caudate nuclei,4,5 globus pallidus,4,5,10,19 red
nuclei,4,5 substantia nigra,4,5 putamen4,5,10,11,19) and dentate
nuclei,5,11 T2 hyperintensity in the striatum and white matter,6
and cerebellar atrophy.6 Brain MRI of an HH patient with
multiple system atrophy, cerebellar type, showed olivopontocerebellar atrophy and cruciform hyperintensity in the pons
(“hot cross bun” sign), but failed to show pathological iron
deposition.12 Few cases had normal MRI scans.8,9,13 One author
describes six patients with systemic HH without neurological
manifestations, but with neuroimaging findings suggestive of iron
deposition.19 This underlines the difficulty in correlating the
neurological features and brain iron deposition in HH patients.
Two of our patients (patients 1 and 2) showed MRI changes
suggestive of iron deposition in the basal ganglia; the third
(patient 3) had iron deposition in the bilateral dentate, red nuclei
and substantia nigra.
Genetic abnormalities in HFE and related proteins may affect
the blood-brain barrier in few patients with HH, leaving their
brain devoid of this protection.13 Thus, the HFE gene mutations
are considered to be the prime contributor of iron overload in
the brain of HH patients,15,20 thereby increasing the risk of neurodegenerative disorders.15,16,21 In addition to the homozygous
HFE mutation (C282Y), the NGS showed an associated mutation
in the CDAN1 gene in patient 1 and HAMP gene in patient 2. The
mutation in the CDAN1 gene is a rare unpublished missense variant that has a relatively low population frequency (National
Heart, Lung, and Blood Institute Exome Sequencing Project: EA:
A = 0.06%; AA: A = 0.02%). The mutation in the HAMP gene has

803

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Figure 2: Brain MRI scan shows T2 hypointensity in both caudate and lentiform nuclei (A), and to a
lesser extent in bilateral dentate nuclei of the cerebellum (C), with corresponding low signal on SWI
(B and D, respectively).

been previously reported in hemochromatosis, but without any
movement disorder or evidence of iron deposition in the brain.22
It is possible that these non-HFE mutations may modify the
phenotypic presentation of the HFE mutation.22 Thus, HFE and
non-HFE mutations leading to iron accumulation in specific
subcortical brain regions may explain the unusual occurrence of
movement disorders in HH.
HH usually involves the liver, pancreas, joints, skin, and gonads.1
Neurological manifestations rarely occur in HH. Neurological
involvement with movement disorders in HH patients, including
parkinsonism,3-6,8,9 Parkinson-plus syndromes,12,13 chorea,7 myoclonus,3,6 ataxia,3,5,6,8,11 dystonia,6,7 and tremor,4-6,10 with mean onset
age of 57 years have been reported (Table 1). Of all the previously
reported patients with HH and movement disorders, two had no major
systemic manifestations.8,13 We report three HH patients, one each
with parkinsonism, chorea, and tremor, without any major systemic
manifestations outside the nervous system. Metabolic disturbances in
systemic HH, mainly from progressive hepatic involvement, can
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often produce neurological features.5,7 All three of our patients had
normal liver function tests and there were no other metabolic
abnormalities apart from the increased blood iron stores. Patient 1 had
evidence of iron deposition in the liver on MRI scan, and patient 3 had
evidence of iron deposition on liver biopsy. However, none of the
three patients had cirrhosis.
The clinical-radiological correlation between the sites of brain
iron deposition and neurological presentations in few reported
cases suggest a causal link between HH and movement
disorders.4,5,11 The stabilization or even reversibility of movement disorders on normalization of iron stores by phlebotomy in
some of the reported cases further strengthens the causal link
between HH and movement disorders.4,8,11 However, there are
other reported cases with HH and movement disorders that failed
to respond to phlebotomy,3,5,6 which may be explained by the
prolonged insult to the brain making the pathology irreversible.11
In one report, a patient showed improvement in fatigue and
headache, and the possibility of improvement in parkinsonism and
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Figure 3: Brain MRI scan shows symmetrical low signal on SWI in the dentate nuclei (A), red nuclei, and
substantia nigra (B).

ataxia was not ruled out as the serum ferritin had not reached
normal levels at the time of reporting the case.5 In another report,
normalization of iron stores with phlebotomy led to reversal
of brain MRI scan findings but the patient’s parkinsonism and
tremor improved only with deep brain stimulation of the right
ventral intermediate nucleus of thalamus.10 All three of our
patients improved with symptomatic drug therapy. Their failure to
respond to normalization of iron stores with phlebotomy may be
explained by the probably irreversible brain pathology resulting
from the prolonged insult during the years of exposure.
The relatively high frequency of HH in Caucasians (0.3%)2,23
highlights the possibility that patients with HH may coincidentally
develop other neurodegenerative movement disorders such as
idiopathic PD and essential tremor.6,7 Few authors have reported
a positive correlation between HH and idiopathic PD.9,24,25
However, larger studies have shown no correlation between HFE
mutation and the risk of idiopathic PD,26-28 and one group
suggested the presence of the C282Y HFE mutation may be
protective against the development of idiopathic PD.26 The
parkinsonism in patient 1 was asymmetrical and resembled
idiopathic PD. However, its development in the setting of
pathological brain iron deposition indicates a secondary cause
related to HH. The initial improvement of parkinsonism with
levodopa can also occur in secondary parkinsonism, such as
vascular parkinsonism29 and Parkinson-plus syndromes such as
multiple system atrophy.30 Thus, a trial of levodopa for parkinsonism associated with HH is indicated. The long-term response
to levodopa in this case, however, is unpredictable.
Other movement disorders have also been reported in HH. We
describe, for the first time, chorea associated with HH. Chorea
was reported in one patient with HH who was later confirmed to
have HD, however.7 The chorea in patient 2 was most likely
attributed to iron deposition in the caudate nuclei. The postural
and action tremor in patient 3 resembled essential tremor.
However, pathological brain iron deposition in the bilateral
dentate nuclei, red nuclei, and substantia nigra suggests her tremor
being likely secondary to HH.
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CONCLUSION
We present three unique cases of HH associated with different
movement disorders. Although two of them had evidence of iron
overload in their liver, none of our patients had any major systemic manifestations. The availability of NGS helps to identify
non-HFE mutations in HH patients, which may act as genetic
modifiers of the phenotypic presentation of HFE mutations. We
report the first case of chorea associated with HH. Patient 1
developed parkinsonism as the initial presentation of HH, which
was levodopa-responsive. Patient 3 presented with head and
bilateral upper extremity tremor responsive to propranolol.
The clinical-radiological correlation between the sites of brain
iron deposition and neurological manifestations is demonstrated
in our HH patients. The literature supports iron deposition in
the basal ganglia and cerebellum on brain pathology in HH.
Finally, the stabilization or reversal of neurological features on
normalization of iron stores by phlebotomy in few reported cases
indicates that the neurological involvement in HH appears to
be more than probabilistic. We propose the term “neurohemochromatosis” for HH patients presenting with predominant
neurological features (movement disorders in our cases) in the
absence of any major systemic manifestations of HH. HH
should be considered in the differential diagnoses of movement
disorders with pathological iron deposition in the brain, because
normalization of iron stores early in the disease process may
result in complete recovery or stabilization of the neurological
manifestations, including movement disorders. In addition
to phlebotomy, appropriate drug treatment depending on the
phenotype of movement disorders should be considered.
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No. of
cases
(M:F)

Onset (years)

Jones et al3

2 (2:0)

71, 52

Movement disorders

Neuroimaging (brain CT/MRI)

Systemic features

∙ Ataxia
∙ Parkinsonism
∙ Myoclonus

∙ BG calcification and
slight sulcal
prominence on
CT brain

∙
∙
∙

Genetic testing

Treatment

DM (n = 1)
Skin pigmentation
(n = 1)
Liver biopsy
suggestive of HH

-

∙ No improvement with
phlebotomy

-

∙ Improvement with levodopa,
amantadine,
anticholinergics, and
phlebotomy

Schroder
et al4

1 (0:1)

75

∙ Parkinsonism
∙ Tremor
∙ Gait disturbance

∙ T2 decrease in GP

∙
∙

Skin pigmentation
Cardiac
insufficiency

Nielsen
et al5

1 (1:0)

26

∙ Parkinsonism
∙ Ataxia
∙ Tremor

∙ T2 decrease in CN,
GP, RN, SN, and DN

∙
∙

Skin pigmentation
Liver MRI and
biopsy
suggestive of HH

∙ HLA-A2,
A3, B7, B44

∙ Levodopa improved
Parkinsonism

Demarquay
et al6

3 (2:1)

56, 31, 70

∙
∙
∙
∙
∙
∙

Ataxia
Parkinsonism
Tremor
Myoclonus
Dystonia
Cognitive decline

∙ Cerebral and
cerebellar atrophy
∙ T2 increase in bilateral
striatum and WM

∙
∙

DM (n = 1)
Skin pigmentation
(n = 1)
Arthritis (n = 1)
Liver biopsy
suggestive of HH

∙ C282Y
homozygous

∙ No improvement with
phlebotomy

Ataxia
Chorea
Dystonia
Cognitive decline

∙ Calcification of
choroid plexus on CT

∙
∙
∙

Abnormal LFT
Skin pigmentation
Liver biopsy showed
iron overload

∙ C282Y
homozygous
∙ Positive HD
gene testing

∙ No improvement with
phlebotomy

∙
∙

Ruso et al7

1 (0:1)

59

∙
∙
∙
∙

Dethy et al8

1 (0:1)

61

∙ Parkinsonism
∙ Ataxia
∙ RLS

∙ Normal

∙

Increased liver
iron on MRI

∙ C282Y

∙ Improvement with
phlebotomy

Costello
et al9

4 (3:1)

55, 61, 62, 63

∙ Parkinsonism

∙ Normal
∙ One patient had vascular lesions on CT

∙
∙

DM (n = 3)
Skin pigmentation
(n = 1)
Abnormal LFT
(n = 1)
Hepatic siderosis

∙ C282Y
∙ HLA-A2
A3 B7 B12

∙ No improvement with
phlebotomy
∙ Levodopa responsive

∙
∙
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Table 1: Reported cases of movement disorders associated with HH including our cases

Volume 43, No. 6 – November 2016

https://doi.org/10.1017/cjn.2016.286 Published online by Cambridge University Press

Rosana
et al10

1 (1:0)

60

∙ Parkinsonism
∙ Tremor

∙ T1 increase and T2
decrease in GP and P
bilaterally

∙
∙
∙

Skin pigmentation
Arthritis on
radiography
Liver biopsy
suggestive of mild
fibrosis

∙ C282Y
homozygous

∙ No improvement with
phlebotomy and levodopa
∙ Improved with DBS

1 (0:1)

69

∙ Chronic
cerebellar ataxia

∙ T2 decrease in
bilateral P and DN

∙
∙

Skin pigmentation
Hepatic siderosis on
CT abdomen

∙ C282Y
homozygous

∙ Stabilized with phlebotomy

Di Filippo
et al12

1 (1:0)

40

∙ MSA-C (ataxia, OH,
abnormal bladder
function)

∙ OPCA
∙ Cruciform hyperintensity in the pons
(“hot cross bun” sign)

∙

Hepatomegaly on
abdominal
examination
Increased liver iron
on biopsy

∙ H63D
homozygous

-

∙ MSA-P
(parkinsonism, OH,
abnormal bladder
function)

∙ Normal

∙

Mild
increase in ALT
Liver positive for
iron (postmortem)

∙ C282Y
homozygous

∙ Deceased

∙ Parkinsonism
∙ Chorea
∙ Tremor

∙ T1 increase in GP and
SN bilaterally
∙ Low signal on SWI in
CN, LN, SN, Th, and
DN bilaterally

Abnormal liver
Fibroscan* (n = 1)
Increased liver iron
on MRI (n = 1), and
biopsy (n = 1)

∙ C282Y
homozygous

∙ Improved with drug
treatment

Williams
et al13

Our study

1 (0:1)

3 (2:1)

60

57, 61, 56

∙

∙
∙
∙

ALT = alanine aminotransferase; BG = basal ganglia; CN = caudate nucleus; DBS = deep brain stimulation; DM = diabetes mellitus; DN = dentate nucleus; F = female; GP = globus pallidus;
HH = hereditary hemochromatosis; HD = Huntington disease; LFT = liver function test; LN = lentiform nucleus; M = male; MSA-C = multiple system atrophy, cerebellar type; MSA-P =
multiple system atrophy, parkinsonian type; OPCA = olivopontocerebellar atrophy; OH: orthostatic hypotension; P: putamen; RLS: restless legs syndrome; RN: red nucleus; SN: substantia nigra;
Th = thalamus; WM = white matter.
*Liver Fibroscan = transient elastography for the measurement of liver fibrosis.
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